Dream Finders Homes, Inc. Class A DFH 深 沪
等待开盘 07-18 09:30:00 美东时间
27.13
+0.190
+0.71%
华盛通- 最 高27.45
- 今 开27.12
- 成交量 25.35万股
- 最 低 26.93
- 昨 收 26.94
- 总市值 25.38亿
- 52周最高 39.1499
- 市盈率 静 8.45
- 换手率 0.27%
- 52周最低 19.6501
- 委 比 -68.00%
- 总股本 9355.40万
- 历史最高 44.38
- 量 比 0.65
- 振 幅 1.93%
- 历史最低 8.17
- 每 手 1
- 风险率 4.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of housing-related stocks are trading higher following a decline in MBA 30-year mortgage rates data, along with an increase in MBA Mortgage Applications data and Mortgage Refinance Index data. This may indicate that more buyers may enter the housing market.
Shares of housing-related stocks are trading higher following a decline in MBA ...
07-10 03:54
快讯 | Dream Finders Homes Inc - 增加股票回购上限至5000万美元 - SEC备案
Dream Finders Homes Inc - Increases Share Buyback Limit to $50 Mln - SEC Filing
06-27 05:15
A Look Into Dream Finders Homes Inc's Price Over Earnings
In the current market session, Dream Finders Homes Inc. (NYSE:DFH) price is at ...
05-24 05:00
Dream Finders Homes Announces Board Member Retirement
Dream Finders Homes ( ($DFH) ) has issued an announcement. On May 8, 2025, Drea...
05-13 05:10
DREAM FINDERS HOMES WINS THE 2025 BUILDER OF THE YEAR AWARD
Strong Acquisitions and Record Revenue Made Dream Finders a Standout Choice NEWPORT BEACH, Calif., April 4, 2025 /PRNewswire/ -- Zonda's BUILDER announced Dream Finders Homes, Inc. ("Dream F...
04-04 21:00
D.R. Horton, Lennar, KB Home, other homebuilders raised to Buy at Seaport
Seaport Research Partners raised its rating recommendations on multiple homebuilders as the firm's bias and rotation toward these stocks trump industry headwinds like margin pressures and falling hous...
03-06 23:48
Dream Finders Homes Reports Record 2024 Earnings
Dream Finders Homes, Inc. ( ($DFH) ) has released its Q4 earnings. Here is a br...
02-27 12:45
美股牛股 | 绩优股狂飙！AdaptHealth大涨24%，Goosehead Insurance涨超15%
绩优股狂飙！AdaptHealth大涨24%，Goosehead Insurance涨超15%；理想汽车飙升13%，宣布推出首款纯电SUV"理想i8">>
02-26 19:07
美股大行评级 | 英伟达获机构上调目标价至220美元！大摩予AKRO“超配”评级
摩根士丹利：维持Akero Therapeutics(AKRO)"超配"评级，目标价从46美元升至96美元
01-29 16:47
